Biocept, Inc.

Biocept, Inc. (Nasdaq: BIOC) develops and performs clinical laboratory tests to help patients with cancer that has metastasized to the central nervous system (CNS). Our CNSide™ assay provides enhanced detection and analysis of tumor cells and cell-free DNA from cerebrospinal fluid (CSF). Quantitative results help evaluate a patient’s response to treatment. Additional biomarkers can characterize genetic changes associated with therapy resistance and identify new options for treating CNS metastasis. CNSide results from Biocept’s CLIA-certified and CAP-accredited laboratory help oncologists manage one of the most difficult complications of cancer, answering three critical questions: Is there tumor in the CSF? Is there a target for treatment? Is there a trend in treatment response? The Biocept team is dedicated to improving care for cancer patients – which means making a difference in people’s lives, every day. Biocept also provides RT-PCR based COVID-19 testing to support state and national public health efforts.

Website

http://www.biocept.com

External link for Biocept, Inc.

Industrie

Biotechnology Research

Größe des Unternehmens

11-50 Mitarbeiter

Hauptsitz

San Diego, California

Typ

Öffentliches Unternehmen

Gegründet

1993

Spezialitäten

Oncology Testing, CTC Testing, ctDNA, laboratory testing, cancer diagnostics, clinical testing, liquid biopsy, clinical services, diagnostic products, testing services, cancer diagnostic development, metastatic breast cancer, non-small cell lung cancer, prostate cancer, colorectal cancer, melanoma, gastric cancer, and molecular testing